To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Broad variability in phar… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Broad variability in pharmacokinetics of GH following rhGH injections in children

Journal article
Authors E. Lundberg
B. Andersson
B. Kristrom
Sten Rosberg
Kerstin Albertsson-Wikland
Published in Growth Hormone & Igf Research
Volume 40
Pages 61-68
ISSN 1096-6374
Publication year 2018
Published at Institute of Neuroscience and Physiology
Pages 61-68
Language en
Keywords Intra-individual variation, Inter-individual variation, GH-deficiency, Non-GH-deficiency, GH-treatment, Cmax, AUC, GH-peak, GH-trough, growth-hormone gh, deficient children, binding-protein, prepubertal, children, pharmacological aspects, hypophysectomized rats, lymphatic, transport, short stature, factor-i, igf-i, Cell Biology, Endocrinology & Metabolism,
Subject categories Clinical Medicine


Objective: Daily subcutaneous self-injection of GH is used worldwide to treat short stature in childhood; longitudinal data on the impact of this regimen on GH-uptake are lacking. Design: Children with/without GH-deficiency participating in clinical trials were followed prospectively ( s 8 times). Blood was sampled pre-GH-injection (dose GH(33)/GH(67) mu g/kg) and either every 30 min thereafter for 24 h (Experimental-setting; 59 GH-curves/15 children); or every 2 h thereafter for 16 h (Clinical-setting; 429 GHcurves/117 children). Pharmacokinetics were estimated by time T-max (h) of maximal GH-concentration (C-max , mU/L) and area under the curve for 16 h (AUC, mU/L * h). Results: In the Clinical-setting, median C-max was 71 mU/L and AUC was 534 mU/L * h, with coefficients of variation for intra-individual variation of 39% and 36%, respectively, and inter-individual variation of 44% and 42%, respectively. 43% of C-max and AUC variability was explained by GH-dose and proxies for injection depth (baseline GH-level, GH(peak) width, BMISDS). In the Experimental- versus Clinical-setting, 85% and 40% of GH-curves, respectively, reached zero-levels within 24 h. A longer duration was found following a more superficial GH-injection. Spontaneous GH-peaks were identified already 6 h after the GH-injection in about half of the curves of both GHD and non-GHD patients. Conclusion: Very broad intra-individual and inter-individual variability was found. A high GH-peak will optimize growth effects; the highest C-max was found after a deep injection of GH at the higher dose and concentration. In as many as 60% of the children, GH remained detectable in serum after 24 h; a constant GH-level will promote IGF-I and metabolic effects.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?